Science and Engineering Ethics

, Volume 19, Issue 3, pp 963–981 | Cite as

Towards a Richer Debate on Tissue Engineering: A Consideration on the Basis of NEST-Ethics

  • A. J. M. Oerlemans
  • M. E. C. van Hoek
  • E. van Leeuwen
  • S. van der Burg
  • W. J. M. Dekkers
Original Paper


In their 2007 paper, Swierstra and Rip identify characteristic tropes and patterns of moral argumentation in the debate about the ethics of new and emerging science and technologies (or “NEST-ethics”). Taking their NEST-ethics structure as a starting point, we considered the debate about tissue engineering (TE), and argue what aspects we think ought to be a part of a rich and high-quality debate of TE. The debate surrounding TE seems to be predominantly a debate among experts. When considering the NEST-ethics arguments that deal directly with technology, we can generally conclude that consequentialist arguments are by far the most prominently featured in discussions of TE. In addition, many papers discuss principles, rights and duties relevant to aspects of TE, both in a positive and in a critical sense. Justice arguments are only sporadically made, some “good life” arguments are used, others less so (such as the explicit articulation of perceived limits, or the technology as a technological fix for a social problem). Missing topics in the discussion, at least from the perspective of NEST-ethics, are second “level” arguments—those referring to techno-moral change connected to tissue engineering. Currently, the discussion about tissue engineering mostly focuses on its so-called “hard impacts”—quantifiable risks and benefits of the technology. Its “soft impacts”—effects that cannot easily be quantified, such as changes to experience, habits and perceptions, should receive more attention.


Hard and soft impacts of technology NEST-ethics Tissue engineering 



The research for this contribution was funded by the European Commission (EuroSTEC: EU contract LSHB-CT-2006-037409).


  1. Adissu, H. A., Asem, E. K., & Lelievre, S. A. (2007). Three-dimensional cell culture to model epithelia in the female reproductive system. Reproductive Sciences, 14(8 suppl), 11–19.CrossRefGoogle Scholar
  2. Awaya, T. (2005). Common ethical issues in regenerative medicine. Journal of International Bioethique, 16(1–2), 69–75, 192–193.Google Scholar
  3. Balharry, D., Sexton, K., & BéruBé, K. A. (2008). An in vitro approach to assess the toxicity of inhaled tobacco smoke components: Nicotine, cadmium, formaldehyde and urethane. Toxicology, 244(1), 66–76.CrossRefGoogle Scholar
  4. Bates, C. (2011). Stem cell patch could save thousands of pregnancies by repairing foetus’ membrane. Daily Mail. Accessed 12 June, 2012.
  5. Baum, B. J., & Mooney, D. J. (2000). The impact of tissue engineering on dentistry. The Journal of the American Dental Association, 131(3), 309–318.Google Scholar
  6. Baylis, F. (2008). Choosing a path: Setting a course for the journey. The American Journal of Bioethics, 8(12), W4–W6.CrossRefGoogle Scholar
  7. Black, J. (1997). Thinking twice about “tissue engineering”. IEEE Engineering in Medicine and Biology Magazine, 16(4), 102–104.CrossRefGoogle Scholar
  8. Boenink, M. S., Swierstra, T., & Stemerding, D. (2010). Anticipating the interaction between technology and morality: A scenario study of experimenting with humans in bionanotechnology. Studies in Ethics, Law and Technology, 4(2), 1–38.CrossRefGoogle Scholar
  9. Bredehorn, T., & Rudolph, B. (2002). Legal problems in tissue transplantation. Transplantation Proceedings, 34(6), 2345–2346.CrossRefGoogle Scholar
  10. Bubela, T. M., & Caulfield, T. A. (2004). Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. Canadian Medical Association Journal, 170(9), 1399–1407.CrossRefGoogle Scholar
  11. Burri, R. (2007). Deliberating risks under uncertainty: Experience, trust, and attitudes in a Swiss Nanotechnology Stakeholder Discussion Group. Nanoethics, 1(2), 143–154.CrossRefGoogle Scholar
  12. Burri, R., & Bellucci, S. (2008). Public perception of nanotechnology. Journal of Nanoparticle Research, 10(3), 387–391.CrossRefGoogle Scholar
  13. Cao, Y., Vacanti, J. P., Paige, K. T., Upton, J., & Vacanti, C. A. (1997). Transplantation of chondrocytes utilizing a polymer-cell construct to produce tissue-engineered cartilage in the shape of a human ear. Plastic and Reconstructive Surgery, 100(2), 297–302.CrossRefGoogle Scholar
  14. Chan, S., & Harris, J. (2006). Cognitive regeneration or enhancement: The ethical issues. Regenerative Medicine, 1(3), 361–366.CrossRefGoogle Scholar
  15. Choumerianou, D. M., Dimitriou, H., & Kalmanti, M. (2008). Stem cells: Promises versus limitations. Tissue Engineering Part B: Reviews, 14(1), 53–60.CrossRefGoogle Scholar
  16. Cogle, C. R., Guthrie, S. M., Sanders, R. C., Allen, W. L., Scott, E. W., & Petersen, B. E. (2003). An overview of stem cell research and regulatory issues. Mayo Clinic Proceedings, 78(8), 993–1003.Google Scholar
  17. Cooper, M. (2004). Regenerative medicine: Stem cells and the science of monstrosity. Medical Humanities, 30(1), 12–22.CrossRefGoogle Scholar
  18. Daar, A. S., Bhatt, A., Court, E., & Singer, P. A. (2004). Stem cell research and transplantation: Science leading ethics. Transplantation Proceedings, 36(8), 2504–2506.CrossRefGoogle Scholar
  19. Daily Mail Reporter. (2011). US Soldier ‘re-grows leg’ after pioneering injection of pig bladder hormone. Daily Mail. Accessed 12 June, 2012.
  20. De Vries, R. B., Oerlemans, A., Trommelmans, L., Dierickx, K., & Gordijn, B. (2008). Ethical aspects of tissue engineering: A review. Issue Engineering Part B: Reviews, 14(4), 367–375.CrossRefGoogle Scholar
  21. Derksen, M. -H. (2008). Engineering flesh, towards professional responsibility for ‘lived bodies’ in tissue engineering. Ph.D. Thesis, Technische Universiteit Eindhoven, Eindhoven.Google Scholar
  22. Derksen, M. -H., & Horstman, K. (2008). Engineering flesh: Towards an ethics of lived integrity. Medicine, Health Care and Philosophy, 11(3), 269–283.CrossRefGoogle Scholar
  23. Dhai, A., Moodley, J., McQuoid-Mason, D. J., & Rodeck, C. (2004). Ethical and legal controversies in cloning for biomedical research—a South African perspective. South African Medical Journal, 94(11), 906–909.Google Scholar
  24. Dickens, B. M., & Cook, R. J. (2007). Acquiring human embryos for stem-cell research. International Journal of Gynaecology and Obstetrics, 96(1), 67–71.CrossRefGoogle Scholar
  25. Ebbesen, M., & Jensen, T. G. (2006). Nanomedicine: Techniques, potentials, and ethical implications. Journal of Biomedical and Biotechnology, 2006(5), 51516.Google Scholar
  26. Edelman, P., McFarland, D., Mironov, V., & Matheny, J. (2005). Commentary: In vitro-cultured meat production. Tissue Engineering, 11(5–6), 659–662.CrossRefGoogle Scholar
  27. Enoch, S., Shaaban, H., & Dunn, K. W. (2005). Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material. Journal of Medical Ethics, 31(1), 2–6.CrossRefGoogle Scholar
  28. EuroSTEC. (2007). European program for soft tissue engineering for congenital birth defects in children. EU contract LSHB-CT-2006-037409.Google Scholar
  29. Faulkner, A., Kent, J., Geesink, I., & FitzPatrick, D. (2006). Purity and the dangers of regenerative medicine: Regulatory innovation of human tissue-engineered technology. Social Science and Medicine, 63(9), 2277–2288.CrossRefGoogle Scholar
  30. Fisk, N. M., Roberts, I. A., Markwald, R., & Mironov, V. (2005). Can routine commercial cord blood banking be scientifically and ethically justified? PLOS Medicine, 2(2), e44.CrossRefGoogle Scholar
  31. Garner, J. P. (2002). Tissue engineering and the trauma surgeon. Trauma, 4(3), 177–183.CrossRefGoogle Scholar
  32. Garner, J. P. (2004). Tissue engineering in surgery. Surgeon, 2(2), 70–78.CrossRefGoogle Scholar
  33. Gaskell, G., Allum, N., Bauer, M., et al. (2000). Biotechnology and the European public. Nature Biotechnology, 18, 935–938.CrossRefGoogle Scholar
  34. Gassei, K., & Schlatt, S. (2007). Testicular morphogenesis. Annals of the New York Academy of Sciences, 1120(1), 152–167.CrossRefGoogle Scholar
  35. Gavelin, K., Wilson, R., & Doubleday, R. (2007). Democratic technologies? The final report of the Nanotechnology Engagement Group (NEG). London: Involve.Google Scholar
  36. Gilbert, J. L. (2011). The dangers in adopting a tissue-engineering-centric agenda: A president’s perspective. Journal of Biomedical Materials Research, Part A, 96(2), 273–274.CrossRefGoogle Scholar
  37. Glotz, P., & Bertschi, S. (2006). People, mobiles and society: Concluding insights from an international expert survey. Knowledge, Technology & Policy, 19(2), 69–92.CrossRefGoogle Scholar
  38. Gordijn, B. (2006). Medical Utopias: Ethical reflections about emerging medical technologies. Leuven: Peeters.Google Scholar
  39. Griffith, L. G., & Swartz, M. A. (2006). Capturing complex 3D tissue physiology in vitro. Nature Reviews Molecular Cell Biology, 7(3), 211–224.CrossRefGoogle Scholar
  40. Gunning, J. (2005). Umbilical cord cell banking—implications for the future. Toxicology and Applied Pharmacology, 207(2 Suppl), 538–543.CrossRefGoogle Scholar
  41. Hall, V., Stojkovic, P., & Stojkovic, M. (2006). Using therapeutic cloning to fight human disease: A conundrum or reality. Stem Cells, 24(7), 137–1628.CrossRefGoogle Scholar
  42. Hammerman, M. R., & Cortesini, R. (2004). Organogenesis and tissue engineering. Transplant Immunology, 12(3–4), 191–192.CrossRefGoogle Scholar
  43. Holm, S. (2006). Are countries that ban human embryonic stem cell research hypocritical? Regenerative medicine, 1(3), 357–359.CrossRefGoogle Scholar
  44. Ihde, D. (1990). Technology and the life world: From garden to earth. Bloomington: Indiana University Press.Google Scholar
  45. Ihde, D. (2002). Bodies in technology. Minneapolis: University of Minnesota Press.Google Scholar
  46. Iijima, K., Igawa, Y., Imamura, T., Moriizumi, T., Nikaido, T., Konishi, I., et al. (2007). Transplantation of preserved human amniotic membrane for bladder augmentation in rats. Tissue Engineering, 13(3), 513–524.CrossRefGoogle Scholar
  47. Irvine, D. J., Stachowiak, A. N., & Hori, Y. (2008). Lymphoid tissue engineering: Invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Seminars in Immunology, 20(2), 137–146.CrossRefGoogle Scholar
  48. Jean, J., Lapointe, M., Soucy, J., & Pouliot, R. (2009). Development of an in vitro psoriatic skin model by tissue engineering. Journal of Dermatological Science, 53(1), 19–25.CrossRefGoogle Scholar
  49. Katz, J. (2006). Mobile communication and the transformation of daily life: The next phase of research on mobiles. Knowledge, Technology & Policy, 19(1), 62–71.CrossRefGoogle Scholar
  50. Kent, J., Faulkner, A., Geesink, I., & FitzPatrick, D. (2006). Culturing cells, reproducing and regulating the self. Body & Society, 12(2), 1–23.CrossRefGoogle Scholar
  51. Kim, S., & von Recum, H. (2008). Endothelial stem cells and precursors for tissue engineering: Cell source, differentiation, selection, and application. Tissue Engineering Part B: Reviews, 14(1), 133–147.CrossRefGoogle Scholar
  52. Kirkpatrick, C. J., Fuchs, S., Hermanns, M. I., Peters, K., & Unger, R. E. (2007). Cell culture models of higher complexity in tissue engineering and regenerative medicine. Biomaterials, 28(34), 5193–5198.CrossRefGoogle Scholar
  53. Kulinowski, K. (2004). Nanotechnology: From “wow” to “yuck”? Bulletin of Science, Technology & Society, 24(1), 13–20.CrossRefGoogle Scholar
  54. Kurtzberg, J., Lyerly, A. D., & Sugarman, J. (2005). Untying the Gordian knot: Policies, practices, and ethical issues related to banking of umbilical cord blood. The Journal of Clinical Investigation, 115(10), 2592–2597.CrossRefGoogle Scholar
  55. Langer, R., & Vacanti, J. P. (1993). Tissue engineering. Science, 260(5110), 920–926.CrossRefGoogle Scholar
  56. Lassen, J., & Jamison, A. (2006). Genetic technologies meet the public. Science, Technology and Human Values, 31(1), 8–28.CrossRefGoogle Scholar
  57. Leabu, M. (2011). Principlism versus utilitarianism in translational medicine ethics. StudiaUBB Philosophia, 56(2), 10.Google Scholar
  58. Levine, A. D. (2010). Insights from patients’ blogs and the need for systematic data on stem cell tourism. American Journal of Bioethics, 10(5), 28–29.CrossRefGoogle Scholar
  59. Li, G. N., & Hoffman-Kim, D. (2008). Tissue-engineered platforms of axon guidance. Tissue Engineering Part B: Reviews, 14(1), 33–51.CrossRefGoogle Scholar
  60. Lomax, G. P., Hall, Z. W., & Lo, B. (2007). Responsible oversight of human stem cell research: The California Institute for Regenerative Medicine’s medical and ethical standards. PLoS Medicine, 4(5), e114.CrossRefGoogle Scholar
  61. Longley, D., & Lawford, P. (2001). Engineering human tissue and regulation: Confronting biology and law to bridge the gaps. Medical Law International, 5(2), 101–115.CrossRefGoogle Scholar
  62. Lowenheim, H., Dazert, S., Bucheler, M., & Guntinas-Lichius, O. (2003). Regenerative medicine/cellular engineering for diseases of the head and neck. DNA and Cell Biology, 22(9), 547–548.CrossRefGoogle Scholar
  63. Marris, C. (2001). Public views on GMOs: Deconstructing the myths. Stakeholders in the GMO debate often describe public opinion as irrational. But do they really understand the public? EMBO Reports, 2(7), 545–548.CrossRefGoogle Scholar
  64. Moise, K. J., Jr. (2005). Umbilical cord stem cells. Obstetrics and Gynecology, 106(6), 1393–1407.CrossRefGoogle Scholar
  65. Moseley, T. A., Zhu, M., & Hedrick, M. H. (2006). Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plastic and Reconstructive Surgery, 118(3 Suppl), 121S–128S.CrossRefGoogle Scholar
  66. Multi-Agency Tissue Engineering Science (MATES), Interagency Working Group (IWG). (2007). Advancing tissue science and engineering. A foundation for the future. A multi-agency strategic plan. Tissue Engineering, 13(12), 2825–2826.Google Scholar
  67. National Institute of Biomedical Imaging and Bioengineering (NIBIB). (2010). Regenerative Medicine Fact Sheet. Accessed 12 June, 2012.
  68. Nerem, R. M. (2006). Tissue engineering: The hope, the hype, and the future. Tissue Engineering, 12(5), 1143–1150.CrossRefGoogle Scholar
  69. Nieminen, O., & Kurki, P. (2004). Risk management for biological products. International Journal of Pharmaceutical Medicine, 18(3), 149–157.CrossRefGoogle Scholar
  70. Oerlemans, A. J., Rodrigues, C. H., Verkerk, M. A., van den Berg, P. P., & Dekkers, W. J. (2010). Ethical aspects of soft tissue engineering for congenital birth defects in children—what do experts in the field say? Tissue Engineering Part B Reviews, 16(4), 397–403.CrossRefGoogle Scholar
  71. Oerlemans, A. J., van den Berg, P. P., van Leeuwen, E., & Dekkers, W. J. (2011). Ethical issues regarding the donation and source of cells for tissue engineering: A European focus group study. Tissue Engineering Part B Reviews, 17(4), 229–234.CrossRefGoogle Scholar
  72. Oerlemans, A. J. M., Feitz, W. F. J., van Leeuwen, E., & Dekkers, W. J. M. (2012). Regenerative urology clinical trials: An ethical assessment of road blocks and solutions (forthcoming).Google Scholar
  73. Olson, J. L., Atala, A., & Yoo, J. J. (2011). Tissue engineering: Current strategies and future directions. Chonnam Medical Journal, 47(1), 1–13.CrossRefGoogle Scholar
  74. Orr, S., Alexandre, E., Clark, B., Combes, R., Fels, L. M., Gray, N., et al. (2002). The establishment of a network of European human research tissue banks. Cell Tissue Bank, 3(2), 133–137.CrossRefGoogle Scholar
  75. Parson, A. (2006). A tissue engineer sows cells and grows organs. New York Times. Accessed 12 June, 2012.
  76. Pascal, P., Damour, O., Colpart, J. J., & Braye, F. (2000). French legal framework relating to human tissues and cells. Medical & Biological Engineering & Computing, 38(2), 241–247.CrossRefGoogle Scholar
  77. Patrick, C. W. (2004). Breast tissue engineering. Annual Review of Biomedical Engineering, 6, 109–130.CrossRefGoogle Scholar
  78. Polak, D. J. (2010). Regenerative medicine. Opportunities and challenges: A brief overview. J R Soc Interface, 7(Suppl 6), S777–781.Google Scholar
  79. Poumay, Y., & Coquette, A. (2007). Modelling the human epidermis in vitro: Tools for basic and applied research. Archives of Dermatological Research, 298(8), 361–369.CrossRefGoogle Scholar
  80. Resnik, D. B. (2002). The commercialization of human stem cells: Ethical and policy issues. Health Care Analysis, 10(2), 127–154.CrossRefGoogle Scholar
  81. Rogers-Hayden, T., & Pidgeon, N. (2006). Reflecting upon the UK’s Citizen’s Jury on nanotechnologies: NanoJury UK. Nanotechnology, Law and Business, 3(2).Google Scholar
  82. Royal Netherlands Academy of Arts and Sciences (Ed.). (2009). Well underway. Opportunities for regenerative medicine in the Netherlands (Vol. 14, Foresight studies). Amsterdam: KNAW.Google Scholar
  83. Salvaterra, E., Lecchi, L., Giovanelli, S., Butti, B., Bardella, M. T., Bertazzi, P. A., et al. (2008). Banking together. A unified model of informed consent for biobanking. EMBO Reports, 9(4), 307–313.CrossRefGoogle Scholar
  84. Samanta, A., Samanta, J., & Price, D. (2004). Who owns my body—thee or me? The human tissue story continues. Clinical Medicine, 4(4), 327–331.CrossRefGoogle Scholar
  85. Satava, R. M. (2003). Biomedical, ethical, and moral issues being forced by advanced medical technologies. Proceedings of the American Philosophical Society, 147(3), 246–258.Google Scholar
  86. Schwab, I. R., Johnson, N. T., & Harkin, D. G. (2006). Inherent risks associated with manufacture of bioengineered ocular surface tissue. Archives of Ophthalmology, 124(12), 1734–1740.CrossRefGoogle Scholar
  87. Siegelbaum, D. (2008). In search of a test-tube hamburger. Time.,8599,1734630,00.html. Accessed 12 June, 2012.
  88. Smith, D. S. (2006). The government’s role in advancing regenerative medicine and tissue engineering—science, safety, and ethics. Periodontol, 2000(41), 16–29.CrossRefGoogle Scholar
  89. Sofaer, N., & Eyal, N. (2010). The diverse ethics of translational research. The American Journal of Bioethics, 10(8), 19–30.CrossRefGoogle Scholar
  90. Solbakk, J. H. (2006). Stem cell research and the ethics of transparency. Regenerative medicine, 1(6), 831–835.CrossRefGoogle Scholar
  91. Stover, D. (2000). Growing hearts from scratch. Popular Science, 46–50.Google Scholar
  92. Svenaeus, F. (2000). The body uncanny—further steps towards a phenomenology of illness. Medicine, Healthcare and Philosophy, 3(2), 125–137.CrossRefGoogle Scholar
  93. Svenaeus, F. (2001). The phenomenology of health and illness. In S. Toombs (Ed.), Handbook of phenomenology and medicine (pp. 87–108). Dordrecht: Kluwer.CrossRefGoogle Scholar
  94. Swierstra, T., & Rip, A. (2007). Nano-ethics as NEST-ethics: Patterns of moral argumentation about new and emerging science and technology. Nanoethics, 1(1), 3–20.CrossRefGoogle Scholar
  95. Swierstra, T., & Te Molder, H. (2012). Risk and soft impacts. In S. Roeser, R. Hillerbrand, M. Petersen, & P. Sandin (Eds.), Handbook of risk theory (pp. 1050–1066). Dordrecht: Springer.Google Scholar
  96. Swierstra, T., Stemerding, D., & Boenink, M. (2009). Exploring techno-moral change: The case of the obesity pill. In P. Sollie & M. Düwell (Eds.), Evaluating new technologies, methodological problems for the ethical assessment of technology developments (pp. 119–138). Dordrecht: Springer.CrossRefGoogle Scholar
  97. Tanaka, Y., Sato, K., Shimizu, T., Yamato, M., Okano, T., & Kitamori, T. (2007). Biological cells on microchips: New technologies and applications. Biosensors & Bioelectronics, 23(4), 449–458.CrossRefGoogle Scholar
  98. Thacker, E. (2002). Bio-X: Removing bodily contingency in regenerative medicine. Journal of Medical Humanities, 23(3), 239–253.CrossRefGoogle Scholar
  99. Thasler, W. E., Weiss, T. S., Schillhorn, K., Stoll, P. T., Irrgang, B., & Jauch, K. W. (2003). Charitable state-controlled foundation human tissue and cell research: Ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank, 4(1), 49–56.CrossRefGoogle Scholar
  100. Thompson, C. (2007). Why we should, in fact, pay for egg donation. Regenerative medicine, 2(2), 203–209.CrossRefGoogle Scholar
  101. Timothy, C. (2004). Biotechnology and the popular press: Hype and the selling of science. Trends in Biotechnology, 22(7), 337–339.CrossRefGoogle Scholar
  102. Trewavas, A., & Leaver, C. (2001). Is opposition to GM crops science or politics? EMBO Reports, 2(6), 455–459.Google Scholar
  103. Trommelmans, L., & Dierickx, K. (2009). Standard of care in clinical research with human tissue engineered products (HTEPs). The American Journal of Bioethics, 9(3), 44–45.CrossRefGoogle Scholar
  104. Trommelmans, L., Selling, J., & Dierickx, K. (2007). A critical assessment of the directive on tissue engineering of the European Union. Tissue Engineering, 13(4), 667–672.CrossRefGoogle Scholar
  105. Trommelmans, L., Selling, J., & Dierickx, K. (2008a). Ethical reflections on clinical trials with human tissue engineered products. Journal of Medical Ethics, 34(9), e1.CrossRefGoogle Scholar
  106. Trommelmans, L., Selling, J., & Dierickx, K. (2008b). Informing participants in clinical trials with ex vivo human tissue-engineered products: What to tell and how to tell it? Journal of Tissue Engineering and Regenerative Medicine, 2(4), 236–241.CrossRefGoogle Scholar
  107. Trommelmans, L., Selling, J., & Dierickx, K. (2009a). An exploratory survey on the views of European tissue engineers concerning the ethical issues of tissue engineering research. Tissue Enginering Part B Reviews, 15(3), 241–247.CrossRefGoogle Scholar
  108. Trommelmans, L., Selling, J., & Dierickx, K. (2009b). Is tissue engineering a new paradigm in medicine? Consequences for the ethical evaluation of tissue engineering research. Medicine, Health Care and Philosophy, 12(4), 459–467.CrossRefGoogle Scholar
  109. Trouet, C. (2004). New European guidelines for the use of stored human biological materials in biomedical research. Journal of Medical Ethics, 30(1), 99–103.CrossRefGoogle Scholar
  110. Tsang, L. (2005). Legal and ethical status of stem cells as medicinal products. Advanced Drug Delivery Reviews, 57(13), 1970–1980.CrossRefGoogle Scholar
  111. Tung, L., & Cysyk, J. (2007). Imaging fibrillation/defibrillation in a dish. Journal of Electrocardiology, 40(6, Supplement 1), S62–S65.Google Scholar
  112. Tveit, G., Madsen, K., & Sandoe, P. (2003). Biotechnology and the public. Danish Centre for Bioethics and Risk Assessment.Google Scholar
  113. Tzanakakis, E. S., Hess, D. J., Sielaff, T. D., & Hu, W. S. (2000). Extracorporeal tissue engineered liver-assist devices. Annual Review of Biomedical Engineering, 2, 607–632.CrossRefGoogle Scholar
  114. Vacanti, C. A. (2006). History of tissue engineering and a glimpse into its future. Tissue Engineering, 12(5), 1137–1142.CrossRefGoogle Scholar
  115. Van Blitterswijk, C. A., Moroni, L., Rouwkema, J., Siddappa, R., & Sohier, J. (2008). Tissue engineering—an introduction. In C. van Blitterswijk, P. Thomsen, A. Lindahl, J. Hubbell, D.F. Williams, R. Cancedda, J.D. de Bruijn, J. Sohier (Eds.), Tissue Engineering (pp. xii–xxxvi). Burlington: Academic Press.Google Scholar
  116. Van der Burg, S. (2009). Taking the “soft impacts” of technology into account: Broadening the discourse in research practice. Social Epistemology, 23(3), 301–316.CrossRefGoogle Scholar
  117. Yoshimura, Y. (2006). Bioethical aspects of regenerative and reproductive medicine. Human Cell, 19(2), 83–86.Google Scholar
  118. Weiss, G. (1999). Body images: Embodiment as intercorporeality. New York/London: Routledge.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • A. J. M. Oerlemans
    • 1
  • M. E. C. van Hoek
    • 1
  • E. van Leeuwen
    • 1
  • S. van der Burg
    • 1
  • W. J. M. Dekkers
    • 1
  1. 1.Scientific Institute for Quality of HealthcareRadboud University Nijmegen Medical CentreNijmegenThe Netherlands

Personalised recommendations